This is a new d-ivacaftor patent listed on Concerts website. This looks like an add on to the original US patent regarding d-ivacaftor for Cystic Fibrosis, except that it has a section that relates to COPD (chronic obstruction pulmonary disease). The added section of the patent is below.
15. A method of treating COPD in a subject comprising administering to the subject a compound of Formula I or a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier, wherein the compound of Formula I has the following structural formula:
Concert is currently assessing the possibility of entering clinical trials for COPD, which would be an extremely large potential market to pursue. The patent runs to 2032. Thank you for reading.
15. A method of treating COPD in a subject comprising administering to the subject a compound of Formula I or a pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable carrier, wherein the compound of Formula I has the following structural formula:
Concert is currently assessing the possibility of entering clinical trials for COPD, which would be an extremely large potential market to pursue. The patent runs to 2032. Thank you for reading.
No comments:
Post a Comment